Signal
After an independent data monitoring committee raised safety flags in a clinical trial, Ipsen is shutting down the cancer med Tazverik, which it picked up th...
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-03-09 14:17 UTCUpdated 2026-03-09 15:38 UTC
rss
biopharma_dive
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme and that it has struggled to sell.
Score total
1.01
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Ipsen to withdraw cancer drug acquired in buyout due to safety concerns
BioPharma Dive · biopharmadive.com · 2026-03-09 15:38 UTC
After an independent data monitoring committee raised safety flags in a clinical trial, Ipsen is shutting down the cancer med Tazverik, which it picked up through its acquisitio...
Fierce Pharma (All) · fiercepharma.com · 2026-03-09 14:17 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Pharma (All) (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercepharma.com (1)